Shopping Cart
- Remove All
- Your shopping cart is currently empty
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $228 | In Stock | |
5 mg | $578 | In Stock | |
10 mg | $826 | In Stock | |
25 mg | $1,220 | In Stock | |
50 mg | $1,650 | In Stock | |
100 mg | $2,230 | In Stock |
Description | Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV). |
Alias | Synagis, MEDI 493 |
Molecular Weight | 144.99 kDa |
Cas No. | 188039-54-5 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.